Prof. Dr. Ozdarendeli: many of the Phase-2 studies in domestic vaccine have been completed
Director of Erciyes University vaccine research and Development Center (ERAGEM) Prof. Dr. Aykut Ozdarendeli reported that domestic vaccine development efforts are continuing.
Prof. Dr. Ozdarendeli, Tekirdag Namik Kemal University Biotocnology community and Faculty of Agriculture Department of Agricultural Biotechnology organized online "6. He participated in biotechnology days" and made a presentation on "Erciyes University Kovid-19 Vaccine Development Studies".
Ozdarendeli, who stated that the effects of the Kovid-19 epidemic were seriously experienced all over the world, said that pandemics in the history of the world were caused by RNA viruses. Ozdarendeli said that the most effective weapon against outbreaks is the development of a vaccine, and important steps have been taken in this sense to combat Kovid-19.
Recalling that vaccine development consists of different processes and steps, Ozdarendeli noted that vaccines include a detailed process from clinical trials to voluntary activities.
Because of the Kovid-19 outbreak, vaccine studies around the world have been very accelerated, Ozdarendeli said, "the vaccine development phase, which will last 10-15 years under Normal conditions, went simultaneously with the Phase-1 study while preclinical studies were continuing, and the Phase-2 and Phase-3 studies went simultaneously. Such work has been and continues to be done around the world. We know that the World Health Organization also allows this." said.
"Vaccine development study continues successfully"
Prof. Dr. Ozdarendeli, supported by the Ministry of Health "inactive against Kovid-19, Adenovector and virus-like particle (VLP) based vaccine candidates development project"began last year and the work continues successfully, he said.
Özdarendeli, who explained that the studies are continuing in Eragem, reminded that Phase-1 and Phase-2 vaccines are applied to volunteers.
Emphasizing that the development of the domestic vaccine is very important, Ozdarendeli noted:
"After the virus was detected in Turkey, we isolated it in a laboratory environment. Then we continued our work by fulfilling the necessary processes. After animal experiments, studies were conducted in Koçak Farma for production. First clinical applications we conducted a Phase-1 study for 44 volunteers at Erciyes University. On November 5, 2020, the first application was made and assessments were made. The most important thing in Phase-1 administration was safety, and no major vaccine-related effects were seen.
Then on February 10, 2021, we started Phase-2 applications, 3 milligrams and 6 milligrams. We finished second on April 9. Currently, many of the studies, such as Phase-2 immune response, have been completed. There is also a serious question of variant. We know that the UK mutant is heavily circulated, especially in our country. So the fact that these vaccine platforms can be adapted to these variants very quickly is another important point of work. In our lab, we have 2 different isolates related to the UK mutant. Our work on it continues."
ERAGEM Müdürü Prof. Dr. Özdarendeli, "10 Şubat 2021'de faz-2 uygulamalarına başladık 3 miligram ve 6 miligram olmak üzere. 9 Nisan'da ikinci dozlamaları bitirdik. Şu anda faz-2'nin immun yanıtı gibi çalışmaların birçoğu bitirildi." dedi. - Anadolu Ajansı
www.aa.com.tr
ekonomi.haber7.com
www.abc.net.au
www.bmc.com.tr
www.bmc.com.tr
www.stern.de
